| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益3.12美元,归母净利润550.15万美元,同比去年增长232.31%
|
| 2024-05-13 |
详情>>
股本变动：
变动后总股本275.01万股
变动原因 ▼▲
- 原因：
- Common stock offered 275,000 shares by the company
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-47.88美元,归母净利润-1610.31万美元,同比去年增长-7.55%
|
| 2024-01-03 |
复牌提示：
2024-01-03 09:34:21 停牌，复牌日期 2024-01-03 09:39:21
|
| 2023-12-18 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-11-13 |
股东大会：
将于2023-12-12召开股东大会
会议内容 ▼▲
- 1.Approval to amend our Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of our common stock, par value $0.0001 (the “Common Stock”), by 50,000,000 shares to 100,000,000 shares;
2.Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from one-for ten (1:10) to one-for-twenty (1:20), at any time prior to the one-year anniversary date of the special meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders (the “Reverse Split”);
3.Ratification of the Company’s entry into a securities purchase agreement on July 18, 2023, with certain purchasers and issuance thereto (the “July 2023 Offering”) of an aggregate of (i) 610,000 shares of Common Stock of the Company, (ii) pre-funded warrants to purchase up to an aggregate of 2,675,000 shares of Common Stock (the “Pre-Funded Warrants”), (iii) common warrants to purchase up to an aggregate of 6,570,000 shares of Common Stock (the “Common Warrants” and, together with the Pre Funded Warrants, the “Warrants”), and (iv) all shares underlying the Warrants (the “Ratification of the July 2023 Offering”);
4.Approval of the adjournment of the Special Meeting of the Stockholders (the “Special Meeting”) to the extent there are insufficient proxies at the Special Meeting to approve any one or more of the foregoing proposals.
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.17美元,归母净利润-1192.51万美元,同比去年增长-8.52%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-3.1美元,归母净利润-844.16万美元,同比去年增长44.72%
|
| 2023-05-15 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.Election of five director nominees named in this proxy statement, each for a term of one year expiring at our 2023 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.Approval of an amendment to our 2020 Omnibus Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder from 317,480 to 1,167,480 and to increase the number of shares that otherwise become available under the plan for grants as incentive stock options (ISOs) to 5,000,000.
3.Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement;
4.Ratification of Mazars USA LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals.
|
| 2023-05-12 |
详情>>
业绩披露：
2023年一季报每股收益-1.82美元,归母净利润-415.81万美元,同比去年增长59.68%
|
| 2023-03-20 |
详情>>
业绩披露：
2022年年报每股收益-21美元,归母净利润-1497.31万美元,同比去年增长82.28%
|
| 2023-01-18 |
详情>>
拆分方案：
每7.0000合并分成1.0000股
|
| 2022-12-16 |
股东大会：
将于2023-01-09召开股东大会
会议内容 ▼▲
- 1.Approval of the issuance of more than 20% of our common stock, par value $0.0001 per share (the “Common Stock”), pursuant to the private placement and warrant amendment for purposes of Nasdaq Listing Rule 5635(d);
2.Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from one-for three (1:3) to one-for-forty (1:40), at any time prior to the one-year anniversary date of the special meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders (the “Reverse Split”);
3.Approval of the adjournment of the Special Meeting of the Stockholders (the “Special Meeting”) to the extent there are insufficient proxies at the Special Meeting to approve any one or more of the foregoing proposals.
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-11.53美元,归母净利润-1098.91万美元,同比去年增长84.99%
|
| 2022-08-26 |
详情>>
拆分方案：
每30.0000合并分成1.0000股
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.82美元,归母净利润-1527.02万美元,同比去年增长64.25%
|
| 2022-07-25 |
股东大会：
将于2022-08-25召开股东大会
会议内容 ▼▲
- 1.Election of six director nominees named in this proxy statement, each for a term of one year expiring at our 2023 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, par value $0.0001 per share (the “Common Stock”), at a specific ratio, ranging from one-for ten (1:10) to one-for-forty (1:40), at any time prior to the one-year anniversary date of the annual meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders(the “Reverse Split”);
3.Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement;
4.Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers;
5.Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals.
|
| 2022-05-23 |
详情>>
业绩披露：
2022年一季报每股收益-0.66美元,归母净利润-1031.26万美元,同比去年增长65.60%
|
| 2022-03-31 |
详情>>
业绩披露：
2021年年报每股收益-9.47美元,归母净利润-8451.86万美元,同比去年增长-102.53%
|
| 2021-11-19 |
股东大会：
将于2021-12-17召开股东大会
会议内容 ▼▲
- 1.Election of six director nominees named in this proxy statement, each for a term of one year expiring at our 2022 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.Approval to amend our Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of our common stock, par value $0.0001 (the “Common Stock”), by 25,000,000 shares to 50,000,000 shares;
3.Ratification of Mazars USA LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals.
|
| 2021-09-10 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2021-01-19 |
股东大会：
将于2021-02-24召开股东大会
会议内容 ▼▲
- 1.Approval, pursuant to Nasdaq Listing Rule 5635, of the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”), upon conversion of our Series C 9.00% Convertible Junior Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”) and other securities in excess of 20% of our Common Stock outstanding;
2.Approval to amend our Amended and Restated Certificate of Incorporation (the “Charter”) to increase the total number of authorized shares of Common Stock by 100,000,000 shares to 250,000,000 shares;
3.Approval to amend our Charter to authorize the Board of Directors (the “Board”) to effect a reverse stock split of both our issued and outstanding and authorized shares of Common Stock, at a specific ratio, ranging from one-for-five (1:5) to one-for-ten (1:10), at any time prior to the one-year anniversary date of the special meeting, with the exact ratio to be determined by the Board (the “Reverse Split”);
4.Approval of the adjournment of the Special Meeting of Stockholders (the “Special Meeting”) to the extent there are insufficient proxies at the Special Meeting to approve any one or more of the foregoing proposals.
|
| 2020-08-07 |
股东大会：
将于2020-09-11召开股东大会
会议内容 ▼▲
- 1.Election of six director nominees named in this proxy statement, each for a term of one year expiring at our 2021 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.Approval of the issuance of more than 20% of shares of our common stock, par value $0.0001 per share (the “Common Stock”) pursuant to a private placement (the “Private Placement”) and related exchange transaction (the “Exchange”), for purposes of Nasdaq Listing Rule 5635(d);
3.Approval of the issuance of shares of our Common Stock to certain officers and directors in the Private Placement and the Exchange, for purposes of Nasdaq Listing Rule 5635(c);
4.Approval of the issuance of more than 20% of our Common Stock pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC, for purposes of Nasdaq Listing Rule 5635(d);
5.Approval of the AzurRx BioPharma, Inc. 2020 Omnibus Equity Incentive Plan;
6.Ratification of Mazars USA LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
7.Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals.
|
| 2019-11-07 |
股东大会：
将于2019-12-19召开股东大会
会议内容 ▼▲
- 1.Election of six director nominees named in this Proxy Statement, each for a term of one year expiring at the Company’s 2020 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.Approval to amend the Company’s Amended and Restated Certificate of Incorporation (“Charter”) to increase the number of authorized shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), by 50,000,000 shares to 150,000,000 shares;
3.Approval to amend the Company’s Charter to authorize the Board to effect a reverse stock split of both our issued and outstanding and authorized shares of the Company’s Common Stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-five (1:5), at any time prior to the one year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board of Directors (the “Reverse Split”);
4.Ratification of Mazars USA LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
| 2018-07-23 |
股东大会：
将于2018-08-27召开股东大会
会议内容 ▼▲
- 1.to elect six directors to our Board of Directors, each to serve until our next annual meeting of stockholders, or until their respective successor is elected and qualified;
2.to ratify the appointment of Mazars USA LLP (formerly, WeiserMazars), as our independent auditors for the year ending December 31, 2018;
3.to vote upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2018-06-29 |
详情>>
内部人交易：
Schramm Vern Lee等共交易4笔
|
| 2017-10-20 |
股东大会：
将于2017-11-28召开股东大会
会议内容 ▼▲
- 1.to elect six directors to our Board of Directors, each to serve until our next annual meeting of stockholders, or until their respective successor is elected and qualified;
2.to ratify the appointment of Mazars USA LLP (formerly, WeiserMazars) , as our independent auditors for the year ending December 31, 2017;
3.to vote upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|